Abbvie Limited

Lobbying Organisation Abbvie Limited

Date published 19 May, 2017

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 Jan, 2017 to 30 Apr, 2017

Specific Details To update on the operations of the IPHA agreement and policy on access to new medicine and deliver our position on the new Biosimilar Policy

Intended results Deliver Abbvie's position on the need for improved policies to better plan the introduction of new innovative medicines in the future and the new Biosimilar Polciy

Name of person primarily responsible for lobbying on this activity Todd Manning and Paula Guerin

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (2-5)

Requesting meeting and agreeing the agenda

Phone call (2-5)

Scheduling the meeting

Meeting (1)

Meeting to update on Industry policy priorities which include the need to build a more sustainable healthcare system , the need for improved policy for access to new medicines and our position on the introduction of a Biosimilar Policy

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Micheál Martin TD (Dáil Éireann, the Oireachtas)